This is a working overview of sublimation, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-24. Anything still debated is marked as such rather than presented as settled.
Freezing is the first stage and sets the ice structure that later becomes the pore network. The formulation is cooled below its freezing point, often with a controlled ramp, and solutes concentrate as ice forms. Primary drying then lowers chamber pressure and supplies heat to sublime the ice. The product temperature must stay below its collapse or eutectic temperature to prevent structural loss. Secondary drying raises the temperature modestly to remove bound water and achieve a low residual moisture.
A freeze-dryer consists of a vacuum chamber, temperature-controlled shelves, a condenser, and a vacuum pump. Vials, ampoules, or bulk trays hold the product during the cycle. The condenser traps water vapor as ice at a temperature lower than the product. Cycle development balances shelf temperature, chamber pressure, and time. Scale-up can be difficult because heat and mass transfer change with equipment size, so process analytical tools and conservative validation are often used.
Lyophilization is a dehydration technique in which a product is frozen and the solvent is removed under reduced pressure. The low pressure allows ice to sublimate directly into vapor without passing through a bulk liquid phase. This differs from conventional drying, where heat drives evaporation and can damage heat-sensitive structures. The process is used for biological materials, pharmaceutical formulations, and some foods. Its main advantage is preservation of porous structure and rapid reconstitution.
Lyophilization is a drying process in which a solvent, usually water, is removed from a frozen material by sublimation under reduced pressure. The material is first solidified, then placed under vacuum so that ice transitions directly to vapor without a bulk liquid phase. This approach suits heat-sensitive substances that would degrade during conventional evaporation. Primary drying removes unbound ice, while secondary drying reduces water that remains adsorbed to the solid matrix. The result is a porous, lightweight solid that can be reconstituted later.
A typical cycle begins with freezing, sometimes including an annealing step to control ice crystal size. Freezing conditions influence the pore network that later allows vapor escape. During primary drying, shelf temperature and chamber pressure are set so heat enters the product while its temperature stays below the collapse or eutectic point. Secondary drying then raises the shelf temperature to desorb bound water and lower residual moisture. Cycle design depends on formulation, fill volume, container type, and equipment capability.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | freeze-drying, lyophilisation, cryodesiccation | Lyophilization is common in pharmaceutical literature. |
| Typical chamber pressure during primary drying | 0.05–0.5 mbar (5–50 Pa) | Must remain below the triple point of water. |
| Typical shelf temperature during freezing | −40 to −20 °C | Lower temperatures may be used for eutectic systems. |
| Typical residual moisture after secondary drying | 0.5–3% w/w | Product-dependent; low moisture improves stability but can cause over-drying. |
| Typical analytical method for residual moisture | Karl Fischer titration or loss on drying | Thermogravimetric methods are also used. |
Lyophilization, also called freeze-drying, removes water from a frozen material by sublimation under reduced pressure. The process begins with freezing, which converts free water into ice and may also produce a glassy phase. Primary drying then lowers chamber pressure so ice sublimes directly to vapor without passing through a liquid stage. Secondary drying raises the temperature modestly to remove bound water. The result is a porous, dry solid that usually reconstitutes quickly. Each stage influences pore structure, residual moisture, and stability.
The physics of lyophilization depends on phase boundaries and heat and mass transfer. During primary drying, heat supplied to the product must equal the latent heat of sublimation, while water vapor moves through the drying cake to the condenser. If shelf temperature or pressure is set too high, the ice front can exceed the collapse temperature, causing meltback or pore collapse. If conditions are too cold, drying slows and costs rise. Formulation excipients, vial geometry, and freezing rate alter these limits.
Equipment for lyophilization includes a vacuum chamber, temperature-controlled shelves, a condenser, and a vacuum pump. A refrigeration system cools the shelves and condenser below the product's freezing point. Process monitoring often uses Pirani and capacitance manometers, thermocouples, and resistance sensors. Cycle development balances product quality with time and energy use. Some products are annealed during freezing to improve crystallization of bulking agents. Open questions remain about scaling cycles between laboratory, pilot, and production freeze-dryers.
Lyophilization removes water by freezing a material and then lowering pressure so ice changes directly to vapor. The process relies on sublimation, the phase transition from solid to gas without an intermediate liquid state. Because the material remains frozen during primary drying, the structure often stays porous. This porous matrix can rehydrate quickly when water is added back. The low pressure also allows vapor to leave the solid matrix without boiling.
A typical cycle begins with freezing, which fixes the material into a solid and determines ice crystal size. Primary drying then raises heat under vacuum so ice sublimes, often near or below the collapse temperature of the formulation. Secondary drying removes bound water that remains after ice is gone, usually by gently warming the product. Each stage balances heat input against pressure to avoid melting or structural damage. Temperature probes and pressure sensors guide the transition between stages.
Lyophilization is a dehydration process that removes water from a frozen material by sublimation under low pressure. The material is first frozen to convert liquid water into ice. Next, the pressure is reduced below the triple point of water so that ice changes directly into vapor without passing through a liquid phase. This step is called primary drying. The result is a porous solid or cake that retains the original shape of the frozen solution.
After primary drying, secondary drying removes water that remains bound to the material. This stage raises the shelf temperature while maintaining low pressure, which encourages desorption of unfrozen water. Residual moisture can be reduced to a low percentage, improving stability for many products. The process parameters, including freezing rate, shelf temperature, and chamber pressure, influence the final pore structure and reconstitution behavior. Control of these variables helps prevent collapse or meltback during drying.
The process usually has three stages: freezing, primary drying, and secondary drying. Freezing sets the ice crystal structure and can determine pore size in the final cake. Primary drying removes free ice by sublimation at low pressure and low shelf temperature. Secondary drying removes bound water by raising the shelf temperature, although some water may remain as part of the solid. Cycle parameters depend on formulation, fill volume, vial type, and equipment performance.
The physical chemistry of freezing influences whether a formulation forms an amorphous glass or a crystalline solid. Amorphous systems can collapse if product temperature rises above the glass transition temperature of the freeze concentrate. Crystalline systems may show eutectic melting, where ice and solute melt together at a fixed temperature. Formulators add bulking agents, lyoprotectants, and buffers to preserve structure and biological activity. The optimum cycle keeps product temperature below critical thresholds during primary drying while allowing efficient sublimation.
=== Photosensitizer === Methylene blue is also a photosensitizer used to create singlet oxygen when exposed to both oxygen and light. It is used in this regard to make organic peroxides by a Diels-Alder reaction which is spin forbidden with normal atmospheric triplet oxygen. With the help of light, methylene blue can be used to kill some viruses and some bacteria. This kind of photo-disinfection has also been done inside of human bodies (antimicrobial photodynamic therapy). The same process can also be used to disinfect blood plasma. Methylene blue is theoretically also applicable to other forms of photodynamic therapy, i.e., the use of oxygen, light, and a photosensitizer to kill cells. Research on using it to kill cancer cells locally is in a preclinical stage. Its cytotoxicity may be related to its ability to inhibit tubulin polymerization.
=== Overlap extension polymerase chain reaction (OEPCR) === The OEPCR method uses a small amount of the gene encoding the monomeric ELP unit and leads to the amplification of this segment to a great extent. This amplification is due to the fact that the initial segment added to the reaction functions as a template, from which identical gene segments can be synthesized. The process will result in the production of double-stranded DNA encoding the ELP of interest. One major bottleneck associated with this method is the potentially low fidelity associated with the Taq polymerase used. This might lead to replication from the template in which the wrong nucleotides are incorporated into the growing DNA strand.
Chemical elements data references List of chemical elements – atomic mass, atomic number, symbol, name List of minerals – Minerals Electron configurations of the elements (data page) – electron configuration, electrons per shell Densities of the elements (data page) – density (solid, liquid, gas) Electron affinity (data page) – electron affinity Melting points of the elements (data page) – melting point Boiling points of the elements (data page) – boiling point Critical points of the elements (data page) – critical point Heats of fusion of the elements (data page) – heat of fusion Heats of vaporization of the elements (data page) – heat of vaporization Heat capacities of the elements (data page) – heat capacity Vapor pressures of the elements (data page) – vapor pressure Electronegativities of the elements (data page) – electronegativity (Pauling scale) Ionization energies of the elements (data page) – ionization energies (in eV) and molar ionization energies (in kJ/mol) Atomic radii of the elements (data page) – atomic radius (empirical), atomic radius (calculated), van der Waals radius, covalent radius Electrical resistivities of the elements (data page) – electrical resistivity Thermal conductivities of the elements (data page) – thermal conductivity Thermal expansion coefficients of the elements (data page) – thermal expansion Speeds of sound of the elements (data page) – speed of sound Elastic properties of the elements (data page) – Young's modulus, Poisson ratio, bulk modulus, shear modulus Hardnesses of the elements (data page) – Mohs hardness, Vickers hardness, Brinell hardness Abundances of the elements (data page) – Earth's crust, sea water, Sun and solar system List of oxidation states of the elements – oxidation states List of compounds List of CAS numbers by chemical compound List of Extremely Hazardous Substances List of inorganic compounds List of organic compounds List of alkanes List of alloys Other List of thermal conductivities List of purification methods in chemistry List of unsolved problems in chemistry
Sources: en.wikipedia.org
Furthermore, myostatin has been shown to directly prevent cell cycle G1 to S phase transition by decreasing levels of cyclin-dependent kinase complex 2 (CDK2) and by increasing p21 levels. Growth of cardiomyocytes may also be hindered by myostatin-regulated inhibition of protein kinase p38 and the serine-threonine protein kinase Akt, which typically promote cardiomyocyte hypertrophy. However, increased myostatin activity only occurs in response to specific stimuli, such as in pressure stress models, in which cardiac myostatin induces whole-body muscular atrophy. Physiologically, minimal amounts of cardiac myostatin are secreted from the myocardium into serum, having a limited effect on muscle growth. However, increases in cardiac myostatin can increase its serum concentration, which may cause skeletal muscle atrophy. Pathological states that increase cardiac stress and promote heart failure can induce a rise in both cardiac myostatin mRNA and protein levels within the heart. In ischemic or dilated cardiomyopathy, increased levels of myostatin mRNA have been detected within the left ventricle. As a member of the TGF-β family, myostatin may play a role in post-infarct recovery. It has been hypothesized that hypertrophy of the heart induces an increase in myostatin as a negative feedback mechanism in an attempt to limit further myocyte growth. This process includes mitogen-activated protein kinases and binding of the MEF2 transcription factor within the promoter region of the myostatin gene.
Eventually, his relationship with intelligence agencies in other countries came to light, and his involvement in drug trafficking was investigated further. In 1988, Noriega was indicted by federal grand juries in Miami and Tampa, Florida, on charges of racketeering, drug smuggling, and money laundering. The U.S. launched an invasion of Panama following failed negotiations seeking his resignation and Noriega's annulment of the 1989 Panamanian general election. Noriega was captured and flown to the U.S., where he was tried on the Miami indictment, convicted on most of the charges, and sentenced to 40 years in prison, ultimately serving 17 years after a reduction in his sentence for good behavior. Noriega was extradited to France in 2010, where he was convicted and sentenced to seven years of imprisonment for money laundering. In 2011, France extradited him to Panama, where he was incarcerated for crimes committed during his rule for which he had been tried and convicted in absentia in the 1990s. Diagnosed with a brain tumor in March 2017, Noriega suffered complications during surgery, and died two months later. Noriega's dictatorship was marked by repression of the media, an expansion of the military, and the persecution of political opponents, effectively controlling the outcomes of any elections. He relied upon military nationalism to maintain his support, and did not espouse a specific social or economic ideology. Noriega was known for his complicated relationship with the U.S., and was described as being its ally and adversary simultaneously.
=== Legal challenges === Nutraceutical Corporation, a supplement manufacturer based in Park City, Utah, challenged the legality of the FDA's ban of Ephedra alkaloids as exceeding the authority given to the agency by the Dietary Health Supplements and Education Act. Nutraceutical Corporation stated that while they did not intend to restart marketing ephedra, they were concerned about the scope of the FDA's regulatory action. Judge Tena Campbell of Utah's Federal District Court ruled that the FDA had not proven that low doses of ephedra alkaloids were unsafe, although she also noted that studies to address the safety of low-dose ephedra would be unethical. Nevertheless, her ruling overturned the ban on the sale of ephedra alkaloids in the state of Utah, and called into question whether the ban could be enforced anywhere in the United States. The ruling was appealed to the U.S. Court of Appeals for the Tenth Circuit in Denver, Colorado. On August 17, 2006, the Appeals Court upheld the FDA's ban on Ephedra alkaloids, finding that the 133,000-page administrative record compiled by the FDA supported the agency's finding that ephedra alkaloids posed an unreasonable risk to consumers. Nutraceutical Corp. filed a petition for a writ of certiorari seeking a rehearing on the ban of ephedra alkaloids; however, on May 14, 2007 the United States Supreme Court declined to hear this petition. The sale of ephedra alkaloid-containing dietary supplements remains illegal in the United States. Sales of products containing ephedra extract not containing ephedrine remain legal.
Sources: en.wikipedia.org
Yes, the terms are generally interchangeable. Lyophilization is more common in pharmaceutical and laboratory contexts, while freeze-drying appears widely in food science and general writing. Both describe removal of solvent by sublimation under vacuum after freezing.
Reduced pressure keeps the process below the triple point of water, so ice can sublimate directly to vapor. It also lowers the temperature needed for drying, which helps preserve heat-sensitive materials. Without vacuum, melting or boiling could occur instead of controlled sublimation.
The rate depends on heat transfer to the product and mass transfer of vapor through the dried layer. A cold condenser, adequate vacuum, and suitable shelf temperature all influence speed. Formulation properties such as solid content and collapse temperature also set practical limits.
Freezing only converts liquid to solid. Lyophilization adds vacuum and controlled warming so frozen solvent sublimes, leaving a dry porous solid. The two steps are related but not interchangeable.